Ilze Bāra
Impact in
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
-
- Lung Cancer Treatments and Mutations 10
- Lung Cancer Diagnosis and Treatment 1
- Oncology 4
- Cancer Immunotherapy and Biomarkers 3
- Lung Cancer Research Studies 1
- Co-authors
- Federico Cappuzzo (2 shared papers)Tony S.K. Mok (4 shared papers)Barbara Klughammer (3 shared papers)Monika D. Kaul (2 shared papers)Wei Yu (2 shared papers)Gaëlle Klingelschmitt (1 shared paper)Martin Reck (1 shared paper)Julien Mazières (1 shared paper)
- Journals
- Journal of Thoracic Oncology (5 papers)Lung Cancer (2 papers)Annals of Oncology (2 papers)JAMA Oncology (2 papers)The Lancet Oncology (1 paper)
- Partner nations
- United StatesSwitzerlandChina
In The Last Decade
Ilze Bāra
15 papers receiving 1.1k citations
Ilze Bāra's Hit Papers
Peers
Comparison fields: 5 of 36
- Pulmonary and Respiratory Medicine 590
- Oncology 255
- Cancer Research 17
- Hepatology 9
- Toxicology 3
Countries citing papers authored by Ilze Bāra
This map shows the geographic impact of Ilze Bāra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilze Bāra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilze Bāra more than expected).
Fields of papers citing papers by Ilze Bāra
This network shows the impact of papers produced by Ilze Bāra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilze Bāra. The network helps show where Ilze Bāra may publish in the future.
Co-authors
The 25 scholars most cited alongside Ilze Bāra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 256 | |
| 2 | Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer Hit paper breakdown → | 2021 | 233 |
| 3 | IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Hit paper breakdown → | 2021 | 231 |
| 4 | 2023 | 134 | |
| 5 | 2013 | 84 | |
| 6 | 2023 | 52 | |
| 7 | 2014 | 34 | |
| 8 | 2020 | 24 | |
| 9 | 2024 | 24 | |
| 10 | 2023 | 11 | |
| 11 | 2021 | 7 | |
| 12 | 2023 | 7 | |
| 13 | 2012 | 2 | |
| 14 | 2014 | 2 | |
| 15 | 2017 | 1 | |
| 16 | 2026 | 0 |
About Ilze Bāra
Ilze Bāra is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Nuclear Energy and Engineering, Waste Management and Disposal and Infectious Diseases, having authored 16 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Diagnosis and Treatment (1 paper) and Lung Cancer Research Studies (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (590 citations), Oncology (255 citations), Cancer Research (17 citations), Hepatology (9 citations) and Toxicology (3 citations). Ilze Bāra has collaborated with scholars based in United States, Switzerland and China. Frequent co-authors include Federico Cappuzzo, Tony S.K. Mok, Barbara Klughammer, Monika D. Kaul, Wei Yu, Gaëlle Klingelschmitt, Martin Reck, Julien Mazières, Peter Middel and Gene Grant Finley. Their work appears in journals such as Journal of Thoracic Oncology, Lung Cancer, Annals of Oncology, JAMA Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.